MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS
STANDARD REFERENCE MATERIAL 1010a
(ANSI and ISO TEST CHART No. 2)
I/We ALTA DIAGNOSTIC MACHINES LIMITED
of Immuno Diagnostic Research Laboratory, The Medical School, University of Birmingham, BIRMINGHAM B15 2TH, ENGLAND
hereby apply for the grant of a Patent for an invention entitled:

METHOD AND APPARATUS FOR THE DETERMINATION
OF THE ANTIBODY CONTENT OF BLOOD

which is described in the accompanying complete specification. This Application is a Convention Application and is based on the Application(s) numbered: 8526355 for a Patent or similar protection made in Great Britain on 25 October 1985

My/Our address for service is:

GRIFFITH HASSEL & FRAZER
71 YORK STREET
SYDNEY N.S.W. 2000
AUSTRALIA

DATED this 22nd day of October, 1986.

ALTA DIAGNOSTIC MACHINES LIMITED
By his/their Patent Attorneys

GRIFFITH HASSEL & FRAZER

TO: THE COMMISSIONER OF PATENTS
COMMONWEALTH OF AUSTRALIA

8981A:rk
COMMONWEALTH OF AUSTRALIA

DECLARATION FOR CONVENTION PATENT APPLICATION

(Note: 1. To be signed by the applicant(s), if individual(s). If applicant is a Company, to be signed by a person on its behalf. 2. This is a comprehensive form, and parts inappropriate to a particular application should be cancelled.)

DECLAREATION IN SUPPORT OF A CONVENTION APPLICATION

FOR A PATENT OR PATENT OF ADDITION

In support of the Convention application No. (a)

made by (b) ALTA DIAGNOSTIC MACHINES LIMITED

Immuino Diagnostic Research Laboratory, The Medical School,
University of Birmingham, Birmingham B15 2TH, England

for a patent/patent of addition for an invention entitled (c)

"METHOD AND APPARATUS FOR THE DETERMINATION OF THE ANTIBODY CONTENT OF BLOOD"

I/We (d) ARTHUR RANDELL BRADWELL, Director of
ALTA DIAGNOSTIC MACHINES LIMITED

c/o BDS Biologicals

Immuno Diagnostic Research Laboratory,
The Medical School,
University of Birmingham, Birmingham B15 2TH.

do solemnly and sincerely declare as follows:

1. I/We (d) am/we are the applicant(s) for the patent/patent of addition
(or, in the case of an application by a body corporate)

2. The basic application(s) as defined by Section 141 of the Act was/were made in the following country or countries on the following date(s) by the following applicant(s)

   a. Great Britain on 25th October 1985
   b. (f)
   c. by (h) ALTA DIAGNOSTIC MACHINES LIMITED
   d. (f)
   e. by (h) ALTA DIAGNOSTIC MACHINES LIMITED
   f. (f)
   g. by (h) ALTA DIAGNOSTIC MACHINES LIMITED

3. I/We are the actual inventor(s) of the invention
(or, where a person other than the inventor is the applicant)

4. The basic application(s) referred to in paragraph 2 of this Declaration was/were the first application(s) made in a Convention country in respect of the invention the subject of the application.

Declared at BIRMINGHAM, ENGLAND this 9 day of OCTOBER, 1986

(b)

Note: No attestation or other signature is required.

The Commissioner of Patents,
The present invention relates to a method of determining the content of a component in a sample of blood, particularly the antigen or antibody content of a sample of whole blood.

Claim

1. A method of quantifying, in a whole blood sample in which the red cells are lysed, a component which will react with a reagent to form an antigen-antibody complex, comprising mixing said sample with said reagent to obtain said complex, exposing said sample to a source of radiation and measuring the intensity of radiation scattered through a given angle by said complex.

6. An apparatus for quantifying an antigen/antibody complex in a whole blood sample in which the red cells have been lysed, including means for receiving said sample which has been treated with a reagent which forms an antigen/antibody complex with a component of the sample, said means being transparent to radiation having a wavelength falling within a given band width, a source of radiation having a radiation within said band width and means for detecting the intensity of said radiation which is scattered through a given angle by the sample.
TO BE COMPLETED BY APPLICANT

Name of Applicant: ALTA DIAGNOSTIC MACHINES LIMITED
Address of Applicant: Immuno Diagnostic Research Laboratory, The Medical School, University of Birmingham, BIRMINGHAM B15 2TH, ENGLAND
Actual Inventor: Arthur Randell Bradwell and Ian Deverill
Address for Service: GRIFFITH HASSEL & FRAZER 71 YORK STREET SYDNEY NSW 2000 AUSTRALIA

Complete Specification for the invention entitled:

METHOD AND APPARATUS FOR THE DETERMINATION OF THE ANTIBODY CONTENT OF BLOOD

The following statement is a full description of this invention, including the best method of performing it known to me/us:-

8981A:rk
METHOD AND APPARATUS FOR THE DETERMINATION OF THE ANTIBODY CONTENT OF BLOOD

The present invention relates to a method of determining the content of a component in a sample of blood, particularly the antigen or antibody content of a sample of whole blood.

Previously proposed methods of determining the antigen content of a sample of blood involve forming a complex between the antigen to be determined and marker antibodies to form agglomerates. These agglomerates will scatter incident radiation and by measuring the intensity of the scattered radiation, the concentration of complex agglomerates, and hence the concentration of antigen can be determined. Typically, the incident radiation has had a wavelength in the ultra-violet part of the spectrum, usually at 290-340 nm where the scattering signal is strong.

However, this method suffers from the problems that there is also a strong scattering at these wavelengths by haemoglobin, and the red blood cells themselves absorb and scatter radiation both of which interfere with the signal from the antigen/antibody agglomerates. Consequently, it has been considered necessary to remove the red blood cells by centrifuging in which case the time taken from obtaining the blood sample to obtaining the results of the analysis is relatively long. Also the use of radiation in the ultra-violet part of the spectrum requires a stable power source to be used which is bulky and requires mains electricity.
It is an object of the present invention to obviate or mitigate the problems outlined above and provide a method of determining the antibody content of whole blood which can be carried out quickly, and in the absence of a mains power supply.

It has been previously proposed to carry out immunological and other blood analyses using a nephelometer. It has also been proposed to utilize a flash light source such as a xenon flash (DE-A-3020677) in such a nephelometer. However, the previously proposed designs of nephelometer suffer from the problems that they are intended for use with existing methods of blood analysis and consequently utilize wavelengths of radiation which either require stabilized power supplies, e.g. ultra violet wavelengths, or wavelengths which would be absorbed by haemoglobin and so require separation of red blood cells or haemoglobin from a blood sample if they are to be useful.

If is a further object of the present invention to provide a nephelometer which can be used to analyse samples of whole blood without the need to remove red blood cells or haemoglobin.

In accordance with a first aspect of the present invention there is provided a method of quantifying, in a whole blood sample in which the red cells are lysed, a component which will react with a reagent to form an antigen-antibody complex, comprising mixing said sample with said reagent to obtain said complex, exposing said sample to a source of radiation and measuring the intensity of radiation scattered through a given angle by said complex.
In a particular embodiment the intensity of said scattered radiation is measured at intervals, to determine the rate of formation of said antigen-antibody complex.

Preferably, the wavelength of the radiation is selected such that it is a wavelength at which the intensity of the radiation scattered through said angle by the antigen/antibody complex is high and the absorption of said radiation by haemoglobin and other proteins is low. It is particularly preferred that the intensity of the scattered radiation is at a local maximum and the absorption of the radiation is at a local minimum.

Typical wavelengths of suitable radiation are 460-530 nm, more preferably 460-510 nm. The red cells are lysed such that they fragment into particles of a size which does not scatter light of these wavelengths and so reduces interference.

Because the methods described in the previous aspects of the present invention do not require centrifuging or an ultraviolet light source and its attendant power supply, it is possible to construct the apparatus for carrying out these methods such that it is portable and relies on an internal power supply.

According to a further aspect of the present invention, there is provided an apparatus for quantifying an antigen/antibody complex in a whole blood sample in which the red cells have been lysed, including means for receiving said sample which has been treated with a reagent which forms an antigen/antibody complex with a component of the sample, said means being transparent to radiation having a wavelength falling within a given bandwidth, typically 460-530 nm, a source of radiation
having a radiation within said band width and means for detecting the intensity of said radiation which is scattered through a given angle by the sample.

Preferably, the apparatus is portable and it is also preferred that the radiation source is a xenon flash tube powered by a dry cell battery. The duration of the flash may be controlled automatically by means of a sensor which monitors the amount of light reflected or transmitted by the sample and which is connected to the source to terminate the flash when sufficient light has been reflected. More particularly, the amount of haemoglobin in the sample is measured by measuring the light transmitted by the sample at a wavelength corresponding to a haemoglobin absorption peak and this measurement is used to control the duration of the flash and so compensate for the red blood cell content of the sample.

The present invention will now be described, by way of example, with reference to the accompanying drawing in which:

Fig. 1 is a chart showing the spectrum of haemoglobin
Fig. 2 is a spectrophotometer scan of a cuvette containing saline, polyethylene glycol, zaponin/KCN and whole blood (line A); the same cuvette two minutes after the addition of anti IgG antiserum (line B); and the interference filter employed in the device described below (line C);

Fig. 3 is a scan showing the relative light scattering, in arbitrary units, of the solutions scanned in lines A and B of Fig 2;

Fig. 4 is a block diagram of an apparatus according to an aspect of the present invention;
Fig. 5 is a block diagram of an apparatus according to the present invention for carrying out simple analyses, Fig. 6 is a block diagram of a further apparatus according to the present invention for carrying out more accurate analyses; and Fig. 7 is a block diagram of an apparatus according to the present invention interfaced with a micro-computer for control and result analysis purposes.

In an example of the present invention, the apparatus comprises a high intensity light source comprising a xenon flash discharge tube 10, such as is typically used in photography powered by a small dry cell. This tube, in conjunction with interference filters and suitable attenuation means 11, 12, gives a narrow band width source of radiation with a maximum at 479 nm. The filters are desired to give a maximum at 473 but production defects may cause a small shift of a few nm from this from filter to filter.

Alternatively, a high intensity output light emitting diode can be used. This has the advantage that the wavelength of the emitted light (e.g. 480 nm) can be controlled quite accurately and so reduces the need for extensive filtering.

A cuvette 13 is charged with 3.0 ml of physiological saline/4 percent polyethylene glycol, 20μl of zaponin/KCN (available from Ortho Pharmaceutical) and 5/1 of whole blood. 40 μl of anti IgG antiseraum is added to this mixture. It is possible to increase the sensitivity of the method according to the present invention by using particle bound antibodies e.g. latex bound antibodies which cause agglomerates to form which scatter radiation more effectively.
The cuvette 13 is made from a suitable transparent material and is placed in the path of the light 16 from the flash tube 10. Because it is not necessary to effect any pre-treatment to the blood sample before it is introduced into the cuvette, it is possible to reduce the amount of handling of the sample to a minimum. This reduces any contact the operator may have with the blood sample to a minimum and so increases the safety of the present method and apparatus.

A photo diode detector 14 is arranged to receive any light 17 which is scattered through a given angle from the sample, in the present case the angle is 90°. The interference filters 11 are placed between the flash tube 10 and the detector 14 such that only light of a specified wavelength is transmitted to the detector 14.

A further detector 15 is positioned to detect light 18 transmitted by the sample at a given wavelength (selected by means of further filters 20) corresponding to haemoglobin absorption. This detector 15 is linked via control circuitry 19 to the flash tube 10 and terminates the flash when sufficient light has been received. This automatically compensates for the red blood cell content of the sample and is not necessary in certain applications of the present invention.

For instance, when it is desired to find the concentration of a particular protein in a sample of whole blood compensation may be needed, whereas if it is desired to find only the concentration of a protein in the serum of a sample the reading no correction for haemoglobin content is required.
Referring now to Figs 1-3, the wavelength of light used is chosen such that the signal from the complex is relatively high and the signal from haemoglobin is at a relative minimum (x) and the total signal relative to background signal is as strong as possible. This is done to ensure that the strength of the signal obtained is mainly effected by the concentration of the complex rather than other incidental factors. In the present case the wavelength chosen is 473 nm (± a few nm due to variations between filters). The detector 14 is linked to a calibrated display 21 such that the signal may be directly displayed in terms of antigen concentration.

Referring now to Fig. 5 those parts which are the same as shown in Fig. 4 are given the same reference numerals in the 100 series. Located within an optical chamber 125 are flash charge and trigger circuitry located within a screened compartment 126 controlling activation of the xenon discharge tube 110, said tube 110, interference filter and illumination aperture 111 and 112, the sample 113, a light sink 127 and the detector 114 in a scatter aperture pipe 128. The light sink 127 serves to absorb any light which is transmitted by the sample and so prevent any reflections within the chamber 125 which may affect the readings. The detector 114 and aperture pipe 128 are arranged in such a way that only light which has been scattered through substantially 90° falls upon the detector 114. The detector 114 emits a signal to a detector amplifier 129 which has means 130 for adjusting the gain on the amplifier 129 and hence allows adjustment of the sensitivity of the apparatus.

A signal from the amplifier 129 is taken to a peak detector 131 which is connected to a timing circuit 132.
provided with adjustment means 133. The timing circuit is also connected to the trigger circuitry in compartment 126. The timing circuit 132 controls the activation of the tube 110 and the peak detector 131. Activation of the timing circuits 132 causes the tube to discharge at a given time after the immunochemical reaction has been initiated in the cuvette 113. The peak detector 131 is activated a short time after the tube 110 is discharged in order to eliminate any e.m.f. peak effects caused by the discharge. The peak detector 131 continues to function until a peak is reached when no more readings are taken.

The signal from the peak detector 131 is fed into a digital multimeter 134 which is provided with controls for zeroing 135 and calibration 136. The readings from the multimeter are shown on a digital display 121.

This apparatus does not cater for compensation for differences between test blanks or in differences in haemoglobin level between samples.

However, such an apparatus can be used satisfactorily in application for detecting the presence or absence of a factor in the sample.

Activation of the timing circuits 132 may be achieved manually by operating a switch when the cuvette 113 has been inserted, or insertion of the cuvette 113 can cause automatic operation by use of a micro-switch.

Referring now to Fig. 6 those parts which correspond to those shown in previous drawings are given the same reference numerals in the 200 series. In this embodiment, the interference filter 211 is located between the cuvette 213 and the detector 214. A
further interference filter 220 is located between the cuvette 213 and the light sink 227. A transmission aperture pipe 240 having a further detector 241 therein is provided in the light sink 227 and is arranged to receive light which has been transmitted through the sample. The signal from the further detector 241 is passed to an associated amplifier 242 which in turn sends a signal to the flash change and trigger circuitry. This arrangement is used to control the duration of the flash in order to compensate for the amount of light absorbed by the haemoglobin in the sample.

The signal from the detector 214 is fed to a peak detector 231 via an amplifier 229 as before, the peak detector being controlled by timing circuitry 232. However, the output from the peak detector is fed through a two-way switch 243 to either a first sample and hold circuit 244 or a second sample and hold circuit 245. Both sample and hold circuits 244, 245 and the switch 243 are controlled by the timing circuits 232. The output of the sample and hold circuits 244, 245 is fed to a digital multimeter 234 with calibration control 236 and displayed on a digital display 221.

In use, a first reading is taken when the immunological reaction is initiated and the switch 243 is operated by the circuit 232 such that the output from the peak detector 231 is fed to the first sample and hold circuits 244. At a pre-set time after this first reading, a second reading is taken and is fed to the second sample and hold circuits 245. The output from the first sample and hold circuits is fed to a zero reference pin on the multimeter 234 and so the output from the second sample and hold circuits 245 can be
displayed to give the change in scatter intensity after
said pre-set time interval, the zero reading being used
to compensate for any scatter from the sample which is
not due to the immunological reaction.

In Fig. 7 parts corresponding to these parts shown in
previous drawings are given the same reference numerals
in the 300 series. The apparatus shown in Fig. 7 is
controlled by a micro computer which handles timing
control and data analysis operations.

In addition to the detectors 314 and 341, an incident
light detector 353 is included to measure the incident
light from the tube 310. This can be used to improve
the accuracy of the apparatus. The output from each
detector 314, 341, 353 is fed to an associated
amplifier 329, 342, 350 and then to a respective peak
detector 331a, 331b, 331c. The output from each peak
detector 331a, 331b, 331c is fed to a multiplexer 354
and then to an analogue-to-digital converter 355 which
is connected to a micro computer 356. The micro
computer 356 replaces the timing circuits shown in
previous embodiments and also controls sample processor
357 which can process the sample accurately before the
readings are taken and so improve overall accuracy.

When there is high interference to the signal from the
complex due to other proteins, it is preferable to use
a rate determining method. In this case, measurements
are taken at specific time intervals after the blood
sample and the antigen are mixed. Typically, a number
of readings over a few seconds and the detected signals
are fed to data analysis means which allows
determination of the rate of formation of the antigen/antibody complex and hence the concentration of the antibody.

Although the present invention has been described with relation to determination of antigen content, it will be clear that this method may also be employed to determine the content of a first antigen protein in a sample of blood by utilizing one or more other antibodies which is specific to the first antibody.
The claims defining the invention are as follows:

1. A method of quantifying, in a whole blood sample in which the red cells are lysed, a component which will react with a reagent to form an antigen-antibody complex, comprising mixing said sample with said reagent to obtain said complex, exposing said sample to a source of radiation and measuring the intensity of radiation scattered through a given angle by said complex.

2. A method as claimed in claim 1, wherein the intensity of said scattered radiation is measured at intervals, to determine the rate of formation of said antigen-antibody complex.

3. A method as claimed in Claim 1 wherein, the wavelength of the radiation is selected such that it is a wavelength at which the intensity of the radiation scattered through said angle by the antigen/antibody complex is high and the absorption of said radiation by haemoglobin and other proteins is low.

4. A method as claimed in Claim 1, wherein the wavelength of radiation is 460-530 nm.

5. A method as claimed in claim 4, wherein the wavelength of radiation is 460 - 510 nm.
6. An apparatus for quantifying an antigen/antibody complex in a whole blood sample in which the red cells have been lysed, including means for receiving said sample which has been treated with a reagent which forms an antigen/antibody complex with a component of the sample, said means being transparent to radiation having a wavelength falling within a given bandwidth, a source of radiation having a radiation within said bandwidth and means for detecting the intensity of said radiation which is scattered through a given angle by the sample.

7. An apparatus as claimed in Claim 6 wherein the said bandwidth is 460-530 nm.

8. An apparatus as claimed in claim 6 which is portable.

9. An apparatus as claimed in Claim 6 wherein the radiation source is a flash source.

10. An apparatus as claimed in Claim 6, wherein the radiation source is a xenon flash tube powered by a dry cell battery.

11. An apparatus as claimed in Claim 9, wherein duration of the flash may be controlled automatically by means of a sensor which monitors the amount of light reflected or transmitted by the sample and which is connected to the source to terminate the flash when sufficient light has been reflected.
12. A method of quantifying, in a whole blood sample in which the red cells are lysed, a component which will react with a reagent to form an antigen-antibody complex, substantially as herein described with reference to the accompanying drawings.

13. An apparatus for quantifying an antigen/antibody complex in a whole blood sample in which the red cells have been lysed substantially as herein described with reference to the accompanying drawings.

Dated this 22nd day of October 1986

ALTA DIAGNOSTIC MACHINES LIMITED
By their Patent Attorney
GRIFFITH HASSEL & FRAZER
hand width, typically 460-530 nm, a source of radiation
Fig. 1 is a block diagram of an apparatus according to an aspect of the present invention;

Fig. 2 is a graph showing the spectral response of the apparatus.

Fig. 3 is a graph showing the relationship between wavelength (nm) and response.
FIG. 5.
FIG. 7.